While announcing the quarterly numbers, the company’s board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
| Subscribe To Our Free Newsletter |
